Comments
Pharma major Ranbaxy Laboratories Ltd on Friday entered into an in-licensing agreement with Gilead Sciences to promote access to low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries.
Gilead will provide a technology transfer for the manufacture of emtricitabine, together with funding to assist with investment in process improvements to reduce manufacturing costs, Ranbaxy said in a filing to the Bombay Stock Exchange.
“The association with Gilead will enable us to offer quality, affordable medicines for treatment of HIV/ AIDS in the developing countries,” Arun Sawhney, Chief Executive Officer and Managing Director, Ranbaxy said.
The company would sell single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.
ronendrasingh.s@thehindu.co.in
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.